Abbott Laboratories (ABT), a medical devices and health care company, on Wednesday revised its annual earnings outlook.
For the full year, the company reaffirmed the midpoint of the previously provided adjusted earnings per share guidance range and narrowed the range to $5.12 to $5.18 per share, which reflects double-digit growth at the midpoint.
On average, 28 analysts polled expect the company to report earnings of $5.14 per share for the year. Analysts' estimates typically exclude special items.
Earlier, Abbott had projected for annual adjusted earnings of $5.10 to $5.20 per share.
Excluding Covid-19 testing-related sales, Abbott has reaffirmed its previously provided full-year organic sales growth guidance of 7.5% to 8%, or 6% to 7%, when including Covid-19 testing-related sales.
ABT was down by 3.35% at $128.24 in the pre-market trade on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.